A.Kim Ritchey, M.D.

  • Professor of Pediatrics, UPMC Children's Hospital of Pittsburgh
  • Vice Chair for International Affairs 
  • Interim Chief, Division of Rheumatology

Editorships

  • Editor-in-chief, Pediatric Treatment Board, Physician Data Query, NCI, NIH

Professional Affiliations/Society Memberships

  • American Society of Clinical Oncology
  • American Society of Hematology
  • American Society of Pediatric Hematology/Oncology
  • COG
  • Thrombosis and Hemostasis Research Society

Education & Training

  • MD: University of Cincinnati College of Medicine Cincinnati, OH
  • Residency: Johns Hopkins University School of Medicine Baltimore, MD
  • Fellowships: Yale New Haven Hospital New Haven, CT

Representative Publications

Research Interests

Children’s Oncology Group (COG). A. Kim Ritchey is an active clinical investigator and local principal investigator (PI) for a number of COG trials at UPMC Children’s Hospital of Pittsburgh. The local PI of a COG trial is responsible for overseeing the research activity of that protocol at the institution. One such trial is testing the efficacy of the tyrosine kinase inhibitor dasatanib when it is added to standard chemotherapy for children with Philadelphia chromosome–positive acute lymphoblastic leukemia. This trial is partially funded by Bristol-Myers Squibb. Ritchey is involved with oversight of the development and performance of pediatric cancer clinical trials at the national level. He is a member of the National Cancer Institute (NCI) Pediatric Leukemia/Lymphoma Steering Committee, which reviews all COG proposals for clinical research in the areas of leukemia and lymphoma. As chair of the COG Data Safety Monitoring Committee, he leads the group which has oversight of all phase 2 and 3 clinical trials.

Ritchey served as local PI for the Pediatric Brain Tumor Consortium, a collaboration of 12 institutions funded by the NCI to offer potentially practice-changing Phase I research for children with brain tumors.

Ritchey served as the local PI for a study of the thrombopoietin agonist romiplostim for children with chronic idiopathic thrombocytopenic purpura.

A. Kim Ritchey has interests in all aspects of hematology/oncology. He continues to care for children and adolescents patients with sickle cell disease, hemophilia, ITP, anemia, leukemia, and other malignancies and has participated in clinical research in all aspects of the field.

Dr. Ritchey's primary research has been in isolated CNS relapse of leukemia and he has led ground-breaking research in the field. He has served in leadership positions locally and nationally including Division Chief of Pediatric Hematology/Oncology at CHP, President of the American Society of Pediatric Hematology/Oncology, Board member of American Board of Pediatrics, Chair of the COG Data Safety Monitoring Committee, member of the NIH Pediatric Leukemia and Lymphoma Steering Committee, and Editor-in-Chief of the Pediatric Treatment Board of the NIH PDQ.

Dr. Ritchey is currently helping to extend the reach of the UPMC Children's Hospital of Pittsburgh outstanding faculty internationally.

Dr. Ritchey's area of clinical expertise is leukemia and hemophilia/coagulation.

Division